Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Steven Cohen's 6 Best Performing Stocks That Still Have Big Upside
Buybacks And Dividends In One ETF
Your Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent (Seeking Alpha)
Related XNPT
Benzinga's M&A Chatter for Monday May 23, 2016
Mid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Nov 2017OppenheimerInitiates Coverage OnOutperform
Nov 2017BMO CapitalMaintainsOutperform
Oct 2017Canaccord GenuityInitiates Coverage OnHold

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!

Partner Center